PHS
STIM icon

PFM Health Sciences’s Neuronetics STIM Stock Holding History

PFM Health Sciences’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,937
Closed -$444K – 114
2018
Q4 		$444K Buy
+22,937
New +$503K 0.01% 92

Other funds holding STIM

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
GE
General Electric Evendale, Ohio $308M AUM 40.86% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PFM Health Sciences's STIM Position: Q1 2019 in Review

PFM Health Sciences sold out of Neuronetics (STIM) in Q1 2019, closing a stake of 22,937 shares — an estimated $444K sold.

PFM Health Sciences first reported a position in STIM in Q4 2018 and held it in 1 quarter. The position peaked at $444K in Q4 2018. 66 funds tracked by Wall St. Rank hold STIM as of Q1 2019.

  • PFM Health Sciences reported no remaining Neuronetics position as of Q1 2019 after selling out during the quarter.
  • PFM Health Sciences sold 22,937 Neuronetics shares in Q1 2019, an estimated $444K.
  • PFM Health Sciences first reported a position in Neuronetics in Q4 2018 and held it in 1 quarter.
  • PFM Health Sciences's Neuronetics position peaked at $444K in Q4 2018.
  • 66 funds tracked by Wall St. Rank held Neuronetics as of Q1 2019.

Based on PFM Health Sciences's 13F filing for Q1 2019, filed 15 May 2019.